Sermorelin vs SLU-PP-332

Sermorelin and SLU-PP-332 are both research peptides studied across multiple applications, but they diverge sharply in their biological targets and evidence bases. Sermorelin, a synthetic fragment of growth hormone-releasing hormone (GHRH), has been extensively studied in human clinical trials, including a landmark 1997 JCEM study demonstrating improvements in IGF-1 and body composition. In contrast, SLU-PP-332 is a small-molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) developed at Washington University in St. Louis, with all current data derived exclusively from murine models. This comparison examines their mechanisms, evidence levels, dosing protocols, and safety profiles to clarify key differences and overlaps for researchers.

Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) that corresponds to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for diagnosing and treating growth hormone deficiency in children, though the product was voluntarily discontinued for commercial reasons—the FDA confirmed in 2013 it was not withdrawn for safety concerns. By preserving the body's natural GH feedback loop via somatostatin, Sermorelin is considered safer than exogenous HGH. The most substantial evidence for its effects in adults comes from a 1997 JCEM trial, which demonstrated improvements in IGF-1, body composition, and well-being over 5 months. Key claims include stimulating endogenous growth hormone release, improving body composition in adults, and enhancing sleep quality.

SLU-PP-332 is a small-molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) developed at Washington University in St. Louis. It activates the aerobic exercise gene program, increasing oxidative muscle fiber content, mitochondrial respiration, and exercise capacity in mice without training. This mechanism represents a fundamentally different approach from AICAR (AMPK activation) by targeting the transcriptional master regulators of oxidative metabolism. CRITICAL: No human trials exist; all data is from murine studies only. Key claims include increasing exercise endurance without training, shifting muscle fiber type toward oxidative phenotype, and protecting against muscular dystrophy in mice. Researchers should note that while the preclinical findings are promising, the translational gap remains substantial.

Both peptides are studied for body composition, but through entirely different pathways. Sermorelin is also researched for anti-aging and sleep, leveraging its GH-releasing properties that may influence metabolic and restorative processes. SLU-PP-332 is additionally investigated for metabolic health, given its role in enhancing oxidative metabolism and mitochondrial function. These overlapping yet distinct research areas highlight the importance of selecting the peptide that aligns with specific mechanistic hypotheses—Sermorelin for GH-mediated effects on body composition and SLU-PP-332 for ERR-driven metabolic adaptations.

Sermorelin is generally well-tolerated in clinical studies, with safety data from published trials supporting a good tolerability profile. Common side effects include injection site reactions (redness, swelling, mild pain) that typically resolve within days. Systemic effects such as headaches, nausea, dizziness, facial flushing, and drowsiness are mild and transient, often occurring in the initial weeks as the body adjusts. In contrast, SLU-PP-332 has no human safety data available; all safety information is derived from mouse studies only. Mice tolerated twice-daily dosing without reported toxicity, but the absence of human trials means that potential risks in humans remain unknown. Researchers should exercise caution and consider the limited evidence base when designing studies with SLU-PP-332.